First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

S. Peters; A. Scherpereel; R. Cornelissen; Y. Oulkhouir; L. Greillier; M.A. Kaplan; T. Talbot; I. Monnet; S. Hiret; P. Baas

doi:10.1016/j.annonc.2022.01.074

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Identifier:nobleid.org/w1/20260526/204B87EB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/204B87EB.svg?ark=w1%2F20260526%2F204B87EB)](https://nobleid.org/work/w1/20260526/204B87EB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Identifier:nobleid.org/w1/20260526/204B87EB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/204B87EB.svg?ark=w1%2F20260526%2F204B87EB)](https://nobleid.org/work/w1/20260526/204B87EB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work